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Introduction
Acute myeloblastic leukemia (AML) is known as a disease
of the elderly, with a median age at diagnosis of between 69
and 72 years.1,2 Age is a well-defined adverse prognostic fac-
tor and elderly AML patients have a dismal prognosis.3,4
Those able to tolerate intensive chemotherapy have com-
plete remission (CR) rates of 40%-65% with a 10%-30%
rate of early deaths. However, responses are short-lived and
median overall survival (OS) is 6-8 months.2-6 Therefore,
these patients represent an unmet medical need. New strate-
gies are required to improve CR rates and, most importantly,
to prolong time to relapse (TTR) and OS. 
Several novel agents have been explored in recent years,
such as FMS-like tyrosine kinase receptor-3 (FLT3) inhibitors,
novel cytotoxic agents, cell cycle inhibitors, monoclonal anti-
bodies, and also hypomethylating agents or histone deacety-
lase inhibitors.7 However, over the last decade, only modest
improvements in the survival of this patient population have
been seen.3
Epigenetic deregulation is a key feature of the pathophysi-
ology of AML, resulting in aberrant transcription of genes
involved in cell growth, proliferation, differentiation, and
apoptosis.8-10 Attempts to restore this epigenetic deregulation
by using hypomethylating agents have been successful, and
have led to the approval of 5-azacytidine and decitabine
based on the positive results obtained in the MDS/AZA-
00111 and DACO-01612 trials, respectively. 
Histone acetylation is another major epigenetic mecha-
nism that is maintained by the correct balance of histone
deacetylases (DACs) and histone acetyltransferases (HATs).13-
15 In leukemic cells, this balance is disrupted by different
mechanisms,16,17 and, therefore, the use of DAC inhibitors
has been proposed as an attractive approach for AML
patients, especially in the elderly population.18,19 
Panobinostat (NVP-LBH-589) is a pan-deacetylase
inhibitor, which demonstrated potent activity against AML
cell lines and primary AML cells, and also potentiated the
action of several standard-of-care anti-AML compounds, par-
ticularly anthracyclines, in experiments performed in our lab-
oratory.20
Here we report the safety and efficacy of the first trial to
evaluate the activity of a DACi, panobinostat, in combina-
tion with chemotherapy followed by a maintenance phase
with DACi in monotherapy in newly diagnosed AML
patients over 65 years of age.
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This phase Ib/II trial combined the pan-deacetylase inhibitor panobinostat with chemotherapy followed by panobi-
nostat maintenance in elderly patients with newly diagnosed acute myeloid leukemia. Patients with prior history of
myelodysplastic syndrome were excluded and 38 evaluable patients were included in the study (median age: 71
years; range: 65-83). Study patients received an induction with idarubicin (8 mg/m2 iv days 1-3) plus cytarabine (100
mg/m2 iv days 1-7) plus panobinostat po at escalating doses (days 8, 10, 12, 15, 17 and 19) that could be repeated in
non-responding patients. Patients achieving complete remission received a consolidation cycle with the same
schema, followed by panobinostat maintenance (40 mg po 3 days/week) every other week until progression. Thirty-
one patients were treated at the maximum tolerated dose of panobinostat in the combination (10 mg) with good tol-
erability. Complete remission rate was 64% with a time to relapse of 17.0 months (12.8-21.1). Median overall survival
for the whole series was 17 months (5.5-28.4). Moreover, in 4 of 5 patients with persistent minimal residual disease
before maintenance, panobinostat monotherapy reduced its levels, with complete negativization in two of them.
Maintenance phase was well tolerated. The most frequent adverse events were thrombocytopenia (25% grades 3/4),
and gastrointestinal toxicity, asthenia and anorexia (mainly grades 1/2). Five patients required dose reduction during
this phase, but only one discontinued therapy due to toxicity. These results suggest that panobinostat is one of the
first novel agents with activity in elderly acute myeloid leukemia patients, and suggest further investigation is war-
ranted, particularly in the context of maintenance therapy. This trial is registered at clinicaltrials.gov identifier: 00840346. 
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Patients over 65 years of age with de novo AML were included
in the trial. Patients were excluded if they had previously received
any antileukemic treatment including a histone deacetylase
inhibitor (HDACi) or if they had had a previous diagnosis of
promyelocytic AML (M3), secondary AML after MDS, or known
brain or leptomeningeal involvement. Patients with a previous his-
tory of cardiomyopathy or significant diarrhea were also excluded
from the trial.
Study design
This was a multicenter, national, open-label, single-arm, non-
controlled study consisting of an initial phase Ib, following the
classic 3+3 schedule, aimed at establishing the maximum tolerated
dose (MTD) of the combination in this patient population. Four
increasing doses of panobinostat (20, 30 and 40 mg with a -1 dose
level at 10 mg) were planned. Once the MTD was defined, recruit-
ment continued at the MTD during phase II to evaluate the safety
and efficacy of the schema.
The initial schema included an induction cycle with idarubicin
(8 mg/m2 days 1-3) + cytarabine (100 mg/m2 days 1-7) in combina-
tion with three weeks of oral panobinostat at escalating doses
(days 8, 10, 12, 15, 17, 19, 22, 24 and 26). A second induction cycle
could be administered in non-responding patients. Patients achiev-
ing CR/CRi received a consolidation cycle with the same schema
followed by maintenance with 40 mg oral panobinostat (3
days/week) for three weeks on and one week off, initially for six
months (this was subsequently amended to be continued until
progression). Following the inclusion of 6 patients, excessive toxi-
city was observed (see Results) and the protocol was amended to
reduce the schedule of panobinostat to two weeks in the induc-
tion cycles (days 8, 10, 12, 15, 17 and 19) and to every other week
in the maintenance phase (Figure 1A). 
The study was approved by the Institutional Review
Board/Independent Ethics Committee of each participating center.
All patients provided written informed consent before screening.
Data were analyzed by the first author; all authors had access to
primary clinical trial data. The trial was registered at
clinicaltrials.gov identifier 00840346. 
Safety assessment and dose-limiting toxicity criteria
Safety was assessed by monitoring all physical, cardiological
and biological adverse events (AEs). They were graded according
to the NCI CTCAE v.3.0.
Dose-limiting toxicity (DLT) was defined as any severe non-
hematologic toxicity considered clinically relevant and related to
the study treatment, occurring during the first 28 days following
the first dose of panobinostat. Specific criteria for DLT are listed in
Online Supplementary Table S1.
Efficacy assessment 
The response to treatment was assessed according to the stan-
dard Cheson criteria.21 The primary efficacy criterion was
response rate [complete response (CR), complete response with
incomplete hematologic recovery (Cri), partial response (PR),
residual disease (RD)], but several other outcomes were also eval-
uated: time to relapse (TTR), duration of response (DOR), relapse-
free survival (RFS), and overall survival (OS). The Kaplan-Meier
method and the log rank test were used to evaluate the statistical
significance of the comparisons. All statistical analyses were per-
formed using SPSS (v.20.0; IBM Corp., Armonk, NY, USA). 
Flow cytometry evaluation of minimal residual disease (MRD)
was performed according to previously described methods.22,23
The LYSIS II and Cell Quest programs (Becton/Dickinson) were
used for data acquisition in FACScalibur and FACS Canto II,
cytometers (Becton/Dickinson, Biosciences San Jose, CA, USA),
and the Infinicyt (Cytognos, Salamanca, Spain) software was used
for further data analysis.
For molecular biological analysis, mutation screening of the
FLT3 and CEBPA genes was performed following published proto-
cols.24-26 NPM1 mutant transcripts and WT1 mRNA levels were
quantified using the MutaQuant and ProfileQuant kits (Ipsogen). 
Results
The initial schema resulted in unacceptable toxicity 
Six patients were included in the initial intensive sched-
ule, which was too toxic for these elderly patients. Three
related deaths were observed: one was due to a renal fail-
ure in induction, a second was due to a fungal sepsis dur-
ing reinduction, and the third involved a septic shock dur-
ing consolidation in a patient in CR. In addition, 2 patients
experienced a significant delay in recovery from the apla-
sia of the induction, which was longer than three months
in one case. Accordingly, the protocol was amended to
reduce the dose of panobinostat in the induction cycles
and in the maintenance phase; the final treatment sched-
ule is shown in Figure 1A. 
Characteristics of the patients included after 
amendment
Forty patients were included in the final schedule, 2 of
whom could not be evaluated due to exclusion criteria
(one had a concurrent diagnosis of multiple myeloma and
the other had base-line QTcF prolongation). Of the 38
evaluable patients in the study cohort, 20 were enrolled in
phase Ib and 18 in phase II. A flow chart of the patients
enrolled in the trial is presented in Figure 1B. Median age
was 71 years (range: 65-83 years) with one-third of
patients being 75 years old or over. Base-line characteris-
tics of the 38 patients are shown in Table 1. 
Determination of the maximum tolerated dose 
of panobinostat in combination with cytarabine 
and idarubicin
Twenty patients were included in the phase Ib dose esca-
lation part of the trial. Seven patients were initially assigned
to dose level one (20 mg of panobinostat). One of them died
on day +7 due to a tumor lysis syndrome, before initiating
panobinostat and therefore was not considered evaluable for
MTD. Two of the 6 MTD-evaluable patients at this dose ful-
filled the DLT criteria: both presented with a G3 hyperbiliru-
binemia, and one of them also had a G3 generalized edema.
According to the protocol, subsequent patients were treated
at the lower -1 dose level (10 mg). No DLT was observed in
the first 3 evaluable patients, and 10 mg was defined as the
MTD of panobinostat in this combination. According to the
protocol, the cohort was expanded with 10 more patients in
phase I, confirming the safety of this combination.
Subsequently, 18 more patients were treated at this same
dose in phase II, with a total of 31 patients treated at the
MTD. Interestingly,  age and other base-line characteristics
of patients included in the 10 mg versus the 20 mg cohorts
were similar. Patients initially treated at 20 mg in phase Ib
continued treatment at this dose if it was tolerated; they will
be reported separately, as they received a dose over the
MTD.
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Panobinostat in combination with idarubicin and
cytarabine at the maximum tolerated dose and 
followed by maintenance produces a favorable 
outcome
Twenty (64%) of the 31 patients treated at the MTD
achieved CR: 17 with the first induction, 2 with reinduc-
tion, and one achieved CRi with reinduction that convert-
ed into CR during maintenance. Three patients (10%)
achieved PR, 5 (16%) presented with refractory disease,
while the remaining 3 (10%) patients were not evaluable
for response due to death in induction. 
The response rate of patients treated at 20 mg was no
better than that obtained with 10 mg panobinostat, with
2 patients each achieving CR, CRi and refractory disease
(29% each), and one death during induction (13%). 
From the 20 patients who achieved CR/CRi at the MTD
dose, one was removed from the study during induction
due to toxicity, and 3 patients died from infectious compli-
cations during consolidation. Therefore, 16 patients start-
ed the maintenance phase with panobinostat monothera-
py. TTR of the 20 patients who achieved CR was 17.0
months (12.8-21.1 months) with a DOR of 16 months
(10.4-21.5 months) and a RFS of 14 months (2.1-25.9
months) (Figure 2A). Figure 2B shows the individual out-
come (time on treatment) of patients who achieved CR
during the treatment. It is interesting to note that 4
patients were still on maintenance therapy at the time of
publication of this report, 15 (2 cases), 22 and 30 months
after inclusion in the trial.
Finally, with a median follow up of 24 months (13-37
months), the median OS was 17 months (5.5-28.4 months)
(Figure 3A), increasing to 21 months (ND-ND) in those
patients achieving CR (Figure 3B). 
Safety of the combination of panobinostat with 
cytarabine and idarubicin at maximum tolerated dose 
Despite the advanced age of this patient population,
treatment at the MTD of panobinostat was safe and
panobinostat did not substantially increase the toxicity
beyond that typical of standard induction chemotherapy
(Table 2). In line with this, no significant delay in recovery
from the aplasia was observed, as the median time to CR
confirmation with normal blood counts was 30 days
(range: 24-56 days). Although patient numbers are small,
those treated at 20 mg required more than 30 days to
recover (32 and 45 days for the 2 patients achieving CR; 37
and 73 days for those achieving CRi), confirming the tox-
icity of the combination at higher doses of panobinostat.
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Table 1. Demographic characteristics of the 38 patients included in
the trial after amendment. 
                                                           N.                           %
Sex                                                                                                        
Male                                                             17                               45%
Age (range)                                                    71 (65-83)
≥70 years                                                    26                               68%
≥75 years                                                    12                               32%
ECOG                                                                                                   
0-1                                                                 36                               95%
2                                                                     2                                 5%
BM blasts                                                                                            
Morphology                                                  44 (20-93)
Flow cytometry                                            45 (4-93)
Hemoglobin                                                    9.3 (7.5-13,7)
Platelets                                                          54 (10-504)
Leukocytes                                                     3.5 (0.9-194)
> 10(x109/L)                                               12                               32%
>50(x109/L)                                                 7                                18%
Type of AML                                                                                        
t(8;21)                                                          1                                 3%
inv 16                                                             1                                 3%
11q23                                                             3                                 8%
AML with trilineage dysplasia                 9                                24%
Minimally differentiated                          1                                 3%
AML without maturation                          6                                16%
AML with maturation                                8                                21%
Acute monocytic AML                               4                                10%
Acute myelomonocytic AML                    2                                 5%
Acute erythroid AML                                 3                                 8%
Cytogenetics                                                                                       
Good / intermediate                                26                               69%
Unfavorable                                                 7                                18%
No metaphases                                          5                                13%
Molecular biology                                                                              
FLT3-ITD                                                      6                                16%
NPM1mutations                                        8                                21%
WT1 overexpression                                24                               63%
CEBPAmutations                                       0                                 0%
ND / NE                                                        8                                21%
ND: not done; NE: not-evaluable; BM: bone marrow.
A
B
Figure 1. (A) Final schema of the panobidara trial. (B) Flow chart of
patients included in the trial.
The main non-hematologic toxicity was gastrointestinal
(GI), with 71% of patients suffering diarrhea, most of
them G1-2 (65%), with only 2 patients (6%) reaching
grade 3. Other common GI toxicities were nausea,
mucositis, dyspepsia and constipation, which were pres-
ent in 40%-50% of cases, again, mainly grades 1 and 2.
Five patients experienced cardiac AEs. Two patients devel-
oped atrial fibrillation, and 2 developed episodes of car-
diac insufficiency with pulmonary edema, one of which
resulted in death. Serial ECGs were performed according
to the protocol and no additional significant abnormalities
were found. 
Overall, 3 (10%) deaths were observed during induc-
tion, all of which were unlikely to have been related to the
treatment under investigation: one patient died from a res-
piratory infection, another from an acute pulmonary
edema before starting panobinostat, and the third from a
fatal head trauma. Three more patients died in CR during
consolidation from serious infectious AEs (only one of
them considered to be treatment-related by the investiga-
tor).
No dose reductions of panobinostat were required dur-
ing these intensive cycles. Apart from the aforementioned
toxic deaths, only one patient discontinued the trial in the
intensive cycles due to toxicity (a septic shock in induction
that occurred before initiating panobinostat).
Panobinostat maintenance is well tolerated in this
patient population
The most important AEs in the maintenance phase are
summarized in Table 3. Overall, treatment was well tol-
erated, with only a minority of patients experiencing
hematologic toxicity; thrombocytopenia was the most
frequent, present in 25% of patients at grades 3/4. The
most important non-hematologic toxicity was again GI
toxicity, especially diarrhea (69% of patients), nausea
(50%) and dyspepsia (31%), but mostly at grades 1 and 2
(Table 3). One-third of the patients experienced low-
grade asthenia or anorexia. Highlighting the safety of this
maintenance phase, only 5 of the 16 patients treated at
the MTD who reached maintenance required dose reduc-
tions of panobinostat during this phase, with one of them
reducing dosage twice (total 6 reduction events). Reasons
for the 6 reductions were hematologic toxicity (2 cases),
GI (2 cases), hematologic and GI AEs (1 case) and investi-
gator decision (1 case). Panobinostat was discontinued
during maintenance in one patient due to a septic shock
in cycle 3.
Efficacy of this treatment in patients with adverse
prognostic features
We also evaluated the extent to which this treatment
overcame adverse prognostic features (Online
Supplementary Figure S1). There were no significant differ-
ences in outcome between patients over or patients below
75 years of age with respect to OS (14 vs. 17 months;
P=0.9); however, a lower CR rate (50% vs. 71%) was
observed in patients over 75 years old, although this was
Panobinostat in elderly AML patients
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Table 2. Most frequent non-hematologic adverse events during the intensive cycles (induction/consolidation), irrespective of the relationship with
the study drugs.
Grades 1/2 Grades 3/4 Grade 5 Total
Gastrointestinal
Diarrhea 20 (65%) 2 (6%) 22 (71%)
Nausea /vomiting 16 (52%) 16 (52%)
Mucositis 12 (39%) 12 (39%)
Dyspepsia 14 (45%) 14 (45%)
Constipation 12 (39%) 12 (39%)
Hemorrhoids 8 (26%) 8 (26%)
Infectious
Febrile neutropenia /sepsis* 18 (58%) 5 (16%) 3 (10%) 26 (84%)
Cellulitis 5 (16%) 5 (16%)
Cardiovascular
Cardiac abnormalities 2 (6%) 2 (6%) 1 (3%) 5 (16%)**
Thrombosis 2 (6%) 2 (6%)
Other
Edemas 17 (55%) 1 (3%) 18 (58%)
Skin rash 16 (52%) 16 (52%)
Liver abnormalities 7 (23%) 1 (3%) 8 (26%)
Asthenia 6 (19%) 2 (8%) 8 (26%)
Hypokalemia 7 (23%) 7 (23%)
*Irrespective of the infectious localization. ** Two G1 ventricular premature complexes; two atrial fibrillations (one G3 and another one G4 as it caused an acute pulmonary edema);
and a G5 acute pulmonary edema.
Table 3. Hematologic and non-hematologic adverse events related to
panobinostat during maintenance.
Grades 1/2 Grades 3/4 Total
Hematologic
Anemia 2 (12%) 2 (12%)
Neutropenia 2 (12%) 2 (12%)
Thrombocytopenia 1 (6%) 4 (25%) 5 (31%)
Gastrointestinal
Diarrhea 10 (63%) 1 (6%) 11 (69%)
Nausea/vomiting 7 (44%) 1 (6%) 8 (50%)
Dyspepsia 5 (31%) 5 (31%)
Other
Asthenia 4 (25%) 1 (6%) 5 (31%)
Anorexia 5 (31%) 5 (31%)
Fever/infections 2 (13%) 1 (6%) 3 (19%)
Skin rash 1 (6%) 1 (6%)
Hyperbilirubinemia 1 (6%) 1 (6%)
not statistically significant (P=0.2). Patients with hyper-
leukocytosis (≥50x109/L leukocytes) had a lower CR rate
(25% vs. 70%) and a worse OS (3 vs. 17 months) than
those without, although neither of these differences were
statistically significant (P=0.1 for both). Patients with
adverse cytogenetic abnormalities or FLT3-ITD had a sig-
nificantly lower CR rate (33% vs. 79%; P=0.04) and a non-
significant trend towards a shorter OS (6 vs. 17 months;
P=0.1). 
Panobinostat maintenance can eradicate minimal
residual disease after induction
To further assess the role of panobinostat monotherapy,
we analyzed its ability to reduce the MRD in patients who
began maintenance in CR but with persistence of residual
disease. Two patients had persistent residual blasts by
flow cytometry at that point. One of them progressed
quickly during the first maintenance cycle. However, the
other patient started the maintenance phase with 0.15%
blasts, having been negative in the previous determina-
tions, and panobinostat monotherapy was able to eradi-
cate the MRD after 3 cycles. This patient remained in
immunophenotypic remission until cycle 18 of mainte-
nance, when he relapsed. 
Regarding molecular biology, 3 patients had a positive
marker at the time of starting maintenance. Panobinostat
E.M. Ocio et al.
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Figure 2. (A) Time to relapse (TTR), duration of response
(DOR), and relapse-free survival (RFS) of the 20 patients
who achieved CR at the MTD. (B) Representation of the time












maintenance was able to reduce the MRD levels in all 3
patients. In the first patient, WT1 transcripts progressively
decreased at three and six months after maintenance, but
the patient progressed in cycle 10. In the second case, the
NPM-1mutation was reduced to almost undetectable lev-
els with panobinostat treatment and is now receiving
cycle 30 as ongoing treatment. The third patient became
NPM-1 negative after the third cycle of maintenance and
is currently on cycle 14 of treatment. 
Discussion
The present trial was based on our previous pre-clinical
experiments in which panobinostat showed a high pre-
clinical antileukemic activity alone and in combination
with anthracyclines.20 We, therefore, decided to test this
hypothesis focusing on fit AML patients aged 65 years or
older, as novel therapeutic approaches are urgently needed
for these patients. The design of the trial was based on the
PETHEMA 99 study, which used exactly the same induc-
tion and consolidation but without panobinostat, and was
followed by an intensification cycle with cytarabine plus
daunorubicin.27,28 As PETHEMA 99 did not include
patients with a previous history of MDS, we decided to
also exclude them from the trial reported here. Patients’
characteristics of both studies were comparable in terms
of adverse prognostic features, such as advanced age
(>75years in 32% vs. 18% of patients, respectively) or
adverse cytogenetics (present in 21% and 25% of evalu-
able patients, respectively). Given the similarities in design
and patient population, we consider it to be a good com-
parator for evaluating the efficacy and safety of the addi-
tion of panobinostat during induction and in the mainte-
nance phase. 
The first finding of the trial was the toxicity in this frail
population, that led to reduce the weeks of administration
of panobinostat after chemotherapy, and made it impossi-
ble to escalate the dose of panobinostat in combination
with cytarabine and idarubicin to over 10 mg.
Consequently, this dose was defined as the MTD.
Nevertheless, when using the MTD, the schema proved to
be feasible, with the expected toxicity associated with
intensive chemotherapy and relatively few early deaths: 3
patients (10%) in induction; and 3 others (10%) in CR dur-
ing consolidation. This is similar, if not better, than the
19% of deaths during induction plus 7% in patients in CR
in post-remission cycles achieved in the previous PETHE-
MA trial. It also compares favorably to the 13% 30-day
mortality rate in the Swedish registry2 and the 20%-30%
8-week mortality rate in the SEER study.6 Moreover,
despite the low dose of panobinostat used, and with the
limitations of a small study, CR rate was 64%. This repre-
sents an improvement on the CR observed in the PETHE-
MA trial (55%) and that of other studies featuring inten-
sive chemotherapy in similar populations (CR rates of
45%-55%).2,6,29 
This study differs from others in the introduction of
maintenance. This is still a controversial issue in AML, but
in recent years, the discovery of novel targeted agents,
some of which are orally administered and have an ade-
quate safety profile, has encouraged research into this
approach, especially in patients with poor prognostic fea-
tures, such as the elderly.30-34 In this trial, we have demon-
strated that panobinostat is a feasible agent for mainte-
nance in AML, since patients were able to remain on treat-
ment for long periods without excessive toxicity. Despite
the high dose of panobinostat administered during main-
tenance (40 mg), few patients required dose reduction,
and, importantly, once this was done, patients could con-
tinue with the treatment. 
The present schema was also effective in delaying the
occurrence of relapse, as the TTR of those patients achiev-
ing CR was 17.0 months, much longer than the 11.7
months achieved in our previous PETHEMA control.
Moreover, in our study, the RFS was 14 months, which is
also better than that reported in a joint analysis of several
trials that used intensive induction (less than 9 months
when focusing on elderly AML patients).35 As further evi-
dence of the efficacy of this agent, panobinostat mainte-
nance was able to decrease the MRD levels in 4 out of 5
patients with eradication of MRD observed in 2 of them.
One of these patients is of particular interest since the MRD
had reappeared just before the maintenance phase, which
may represent the first sign of potential relapse. However,
the initiation of panobinostat maintenance reverted this sit-
uation, eradicating the disease for a second time and main-
taining the patient relapse-free for a further 18 months. 
Finally, the most important challenge in the treatment of
elderly AML patients is to improve survival, as, even when
receiving intensive treatment, they have a median OS of
less than one year (usually 6-8 months).2-6 This was also
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Figure 3. (A). Overall survival of patients treated at the maximum tol-
erated dose. (B). Overall survival in patients who achieved CR (n=20)
versus those who did not (n=11). 
A
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the case in the previous PETHEMA 99 trial in which OS
was 7.6 months. Interestingly, in our study, OS was 17
months, twice that reported for other trials (see above).
Moreover, in those patients achieving CR, median OS was
21 months, which is also clearly superior to the 14.5
months of the PETHEMA trial. 
In conclusion, our data demonstrate the safety and effi-
cacy of panobinostat in combination with cytarabine and
idarubicin, followed by a maintenance phase with panobi-
nostat in monotherapy. The whole schema, including the
maintenance phase, was able to improve the CR rate and
the TTR of responding patients and, subsequently, the OS
compared with previous controls, with a good tolerability.
Moreover, although it was not implemented in our trial,
the future evaluation of some biomarkers, such as histone
or tubulin acetylation, could help to better define those
patients that could benefit the most from deacetylase
inhibitors such as panobinostat. These results identify
panobinostat as one of the first novel agents with poten-
tial activity in elderly AML patients.
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